Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while ...

Throughout my 25-year career in clinical oncology and translational cancer research, I have frequently encountered financial ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical ...

Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and ...

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast ...

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in ...

FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target ...

During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid ...